Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 10 of 10 entries
View as:

A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Phase: N/A Priority: Normal
NCT ID: NCT05288504 Org: User:
Start: 02/24/22 End: 05/11/23 Due: 05/11/24

A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01579526 Org: User:
Start: 04/30/12 End: 05/31/12 Due: 05/31/13

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT03169894 Org: User:
Start: 07/14/17 End: 10/12/21 Due: 10/12/22

An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough

Phase: N/A Priority: Normal
NCT ID: NCT01703923 Org: User:
Start: 11/30/12 End: 09/30/13 Due: 09/30/14

A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations

Phase: N/A Priority: Normal
NCT ID: NCT04994002 Org: User:
Start: 09/03/21 End: 06/30/22 Due: 06/30/23

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

Phase: N/A Priority: Normal
NCT ID: NCT06603077 Org: User:
Start: 09/16/24 End: 07/31/26 Due: 07/31/27

Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respiratory Tract Infection

Phase: N/A Priority: Normal
NCT ID: NCT01597349 Org: User:
Start: 05/31/12 End: 09/30/12 Due: 09/30/13

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01941043 Org: User:
Start: 11/30/13 End: 10/31/14 Due: 10/31/15

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT04671251 Org: User:
Start: 12/15/20 End: 03/30/22 Due: 03/30/23

A Study of Intermittent Doses of CERC-301 in MDD

Phase: N/A Priority: Normal
NCT ID: NCT02459236 Org: User:
Start: 06/30/15 End: 12/31/16 Due: 12/31/17